News

Stay up to date with insights and updates from Black Swan Biotech, our patients and our partners.

No items found.

Black Swan Biotech Holding Pty Ltd Appoints Mr Aaron Brinkworth as Independent Non-Executive Director

Taking a precision approach to treat MND / ALS

Black Swan Biotech Holding Pty Ltd Appoints Dr. Ahmad Al Khleifat (King’s College London, UK) as Clinical Advisor and Chair of Clinical Advisory Board.

Black Swan Biotech Holding Pty Ltd Secures investment from Western Australian Venture Fund.

Black Swan Biotech Holding Pty Ltd Appoints FundWA’s Prof Michael Nguyen as Non-Executive Director Following FundWA Investment

The Story of the Black Swan

Entering the era of precision medicine to treat amyotrophic lateral sclerosis

To splice or not to splice: pseudoexons in neurological disease and opportunities for intervention

Allele Selective and splice-switching FUS targeted antisense oligonucleotide therapeutic development for ALS

We cannot continue to ignore heterogeneity in ALS

BSP 0001: A novel SOD1 antisense therapy for SOD1-linked and sporadic ALS

Entering the era of precision medicine to treat amyotrophic lateral sclerosis

To splice or not to splice: pseudoexons in neurological disease and opportunities for intervention

Allele Selective and splice-switching FUS targeted antisense oligonucleotide therapeutic development for ALS

BSP 0001: A novel SOD1 antisense therapy for SOD1-linked and sporadic ALS

Full list of team publications

Black Swan Biotech Holding Pty Ltd Appoints Mr Aaron Brinkworth as Independent Non-Executive Director

Black Swan Biotech Holding Pty Ltd Appoints Dr. Ahmad Al Khleifat (King’s College London, UK) as Clinical Advisor and Chair of Clinical Advisory Board.

Black Swan Biotech Holding Pty Ltd Secures investment from Western Australian Venture Fund.

Black Swan Biotech Holding Pty Ltd Appoints FundWA’s Prof Michael Nguyen as Non-Executive Director Following FundWA Investment

No items found.

Taking a precision approach to treat MND / ALS

We cannot continue to ignore heterogeneity in ALS

The Story of the Black Swan

Join us in the fight against ALS

Whether you're interested in research collaboration, strategic partnerships, investment opportunities, or learning more about our technology, we'd love to hear from you.

© 2026 Black Swan Biotech Holdings Pty Ltd